Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of DEC003M, an Antibody Drug Conjugate Targeting PSMA, for Advanced Stage Prostate Cancer

NCT07657806 is registered in ClinicalTrials.gov with Hangzhou DAC Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07657806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07657806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of DEC003M, an Antibody Drug Conjugate Targeting PSMA, for Advanced Stage Prostate Cancer
Lead sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
August 19, 2026
Completion date
May 1, 2031
Enrollment
110 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer